

IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Previously Presented): A hyperlipemia therapeutic agent comprising a pitavastatin and eicosapentaenoic acid or an ester thereof as effective ingredients each in an effective amount.

Claim 2 (Previously Presented): The hyperlipemia therapeutic agent as described in claim 1, wherein the pitavastatin is a calcium pitavastatin.

Claim 3 (Previously Presented): The hyperlipemia therapeutic agent as described in claim 1 or 2, wherein the eicosapentaenoic acid ester is ethyl eicosapentaenoate.

Claim 4 (Canceled).

Claim 5 (Previously Presented): A composition for treatment of hyperlipemia comprising an effective amount of each of a pitavastatin, eicosapentaenoic acid or an ester thereof and a pharmaceutically acceptable carrier.

Claim 6 (Previously Presented): A method for treating hyperlipemia in a patient in need of such treatment comprising administering an effective amount of each of a pitavastatin and eicosapentaenoic acid or an ester thereof.

Claim 7-9 (Canceled)

Claim 10 (Currently Amended): A blood triglyceride decreasing A hyperlipemia therapeutic agent according to claim 1 [[7]] which agent is a blood-triglyceride decreasing agent, wherein the pitavasitin is pitavastin calcium and the eicosapentaenoic acid or ester thereof is ethyl-eicosapentaenoate eicosapentaenoate.